


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/19, 15/79, 5/10, A61K 38/19	A1	(11) International Publication Number: WO 00/00612 (43) International Publication Date: 6 January 2000 (06.01.00)
(21) International Application Number: PCT/KR99/00347		Sanbon-dong, Koonpo-si, Kyunggi-do 435-040 (KR). PARK, Seung, Kook [KR/KR]; #409 Sanho Apt., San 19-4 Sangdaewon-dong, Joongwon-ku, Sungnam-si, Kyunggi-do 463-120 (KR). KOH, Yeo, Wook [KR/KR]; #126-601 Shibom Hanshin Apt., Seohyun-dong, Pundang-ku, Sungnam-si, Kyunggi-do 463-050 (KR). PARK, Ji, Soo [KR/KR]; 538-59 Donam-dong, Sungbuk-ku, Seoul 136-060 (KR).
(22) International Filing Date: 30 June 1999 (30.06.99)		
(30) Priority Data: 199825935 30 June 1998 (30.06.98) KR 199925143 29 June 1999 (29.06.99) KR		
(71) Applicant (<i>for all designated States except US</i>): DAEWOONG PHARMACEUTICAL CO., LTD. [KR/KR]; 163-3 Sung-sung-dong, Kangnam-ku, Seoul 135-715 (KR).		(74) Agent: LEE, Won-Hee; Suite 805, Sung-ji Heights II, 642-16 Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).
(72) Inventors; and		
(75) Inventors/Applicants (<i>for US only</i>): CHUNG, Joo, Young [KR/KR]; #210-1204 Hanshin Apt., Imae-dong, Pundang-ku, Sungnam-si, Kyunggi-do 463-060 (KR). PARK, Sang, Kyu [KR/KR]; 177-3 Mook-1-dong, Chungrang-ku, Seoul 131-141 (KR). JU, Sang, Myoung [KR/KR]; #408-401 Hansol Jookong Apt., Chongja-dong, Pundang-ku, Sungnam-si, Kyunggi-do 463-010 (KR). AHN, Hyca, Kyung [KR/KR]; #609-1305 Imaechon Chongku Apt., Imae-dong, Pundang-ku, Sungnam-si, Kyunggi-do 463-060 (KR). LIM, Seung, Wook [KR/KR]; #106-702 Doosan Apt., 2024 Shinheung-dong, Soojung-ku, Sungnam-si, Kyunggi-do 461-160 (KR). CHANG, Woo, Ik [KR/KR]; #409-1103 Halla Jookong Apt, 1156-1	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CI, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <i>With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.</i>

(54) Title: A NOVEL HUMAN THROMBOPOIETIN MUTANT



(57) Abstract

The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production *in vivo*. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A NOVEL HUMAN THROMBOPOIETIN MUTEIN

FIELD OF THE INVENTION

The present invention relates to novel human thrombopoietin (; hTPO) derivatives with high activities enhancing the platelet production in vivo, and to process of preparation thereof.

Particularly, this invention relates to novel hTPO derivatives wherein sugar chains are introduced by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO; to nucleotide sequences encoding the hTPO derivatives; to expression vectors containing the nucleotide sequences; to process of construction thereof; to cell lines transformed with the vectors; and to process of preparing the hTPO derivatives thereby.

BACKGROUND

Thrombocytopenia is the disease of platelet deficiency caused by anticancer therapy, bone marrow graft and so on. In the process of anticancer therapy or bone marrow graft, megakaryocyte colony forming cells, the platelet precursor cells in bone marrow, are disrupted, and this leads to platelet deficiency.

Thrombocytopenia patient is subject to bleeding in

response to a light trauma, and more serious patient becomes bleeding without trauma. Bleeding is often fatal in this case since the blood is not stanchered at all.

5 The current therapy for thrombocytopenia is nothing but the platelet transfusion. However, several problems and side effects are associated with this therapy, such as insufficient donors, transfusion-mediated infection with e.g. HIV (human
10 immunodeficiency virus) and hepatitis viruses, the elicitation of immune response, and so on.

Platelet is a component of blood, originated from megakaryocyte precursor cells, and plays a role in the suppression of bleeding. Thrombopoietin (hereafter, referred to as "TPO"), a glycoprotein synthesized and secreted in liver or kidney, regulates the platelet level in blood. TPO accelerates the proliferation and differentiation of the megakaryocyte precursor cells,
15 which is followed by the platelet production (Lok et al., Nature, 369: 565-568, 1994; De savage et al., Nature, 369: 533-568, 1994).
20

Since a gene encoding TPO was isolated first from human in 1994 (Lok et al., Nature, 369: 565-568, 1994;
25 De savage et al., Nature, 369: 533-568, 1994; Miyazaki et al., Experimental hematol., 22: 838, 1994; WO 95/18858), clinical approaches for thrombocytopenia

have been based on the function of human TPO (hereinafter, referred to as "hTPO"), that is, the regulation of the platelet level.

5 Three different approaches are proceeded in order to improve the activity of native hTPO.

Glycoprotein hTPO is expressed in cells as an inactive precursor comprising 353 amino acids, and the cleavage of signal peptide (21 amino acids) leads to
10 the secretion of active hTPO protein (332 amino acids) out of the cells. The amino acid sequence of hTPO is divided into two regions. The N-terminal region comprising 151 amino acids contains catalytic site, and shows high similarity to that of erythropoietin (; EPO).
15 The other region, C-terminal region is presumed to have a key role in the extracellular secretion and in vivo stability of hTPO.

The first method for modifying native hTPO relates to the deletion of the C-terminal region or the
20 addition of new amino acids to the deleted hTPO.

In support of this approach, Amgen INC. developed various hTPO derivatives such as hTPO₁₋₁₅₁ (consisting of amino acids 1-151), hTPO₁₋₁₇₄ (consisting of amino acids 1-174) and the hTPO₁₋₁₅₁ supplemented with methionine-
25 lysine in its N-terminal. However, these derivatives proved to show lower hTPO activity in vivo than native hTPO, although their activities were maintained in

vitro (WO 95/26746, WO 95/25498).

In addition, Genentech INC. prepared from *E. coli* a recombinant hTPO₁₆₂ derivative having an N-terminal methionine (WO 95/18858). Kirin produced diverse hTPO derivatives with C-terminal deletion and hTPO₁₆₂ derivatives with substitution, deletion, or insertion at a specific amino acid residue (WO 95/21920). Other hTPO derivatives with C-terminal deletion were provided by ZymoGenetics INC. (WO 95/21920; WO 95/17062) and G. 10 D. Searl (WO 96/23888). These derivatives, however, failed to show higher activity of platelet production in vivo than native hTPO.

The second method is associated with the conjugation of polyethyleneglycol (; PEG) with hTPO fragment, which is exemplified by hTPO₁₆₂-PEG of Amgen INC. 15 (WO 95/26746).

The derivatives according to this method, however, have critical handicaps such as poor stability and safety, since they do not contain C-terminal region 20 that is important for the stability of hTPO and since immune response may be elicited by the shift of their folding structures. Moreover, the qualities of products may be uneven because PEG is not so conjugated at a uniform proportion.

25 The third method exploits the glycosylation of hTPO, which may increase the hTPO activity.

Amgen INC. performed a mutagenesis where a

specific nucleotide in cDNA encoding hTPO was substituted to bear amino acid sequence "Asn-X-Ser/Thr" (where X is any amino acid but proline). The mutated gene was used to prepare hTPO derivatives with C-terminal deletion, which comprised 174 amino acids and into which one or more N-linked glycosylation sites are produced (WO 96/25498).

10 Korea Research Institute of Biology and Biotechnology (KRIBB) produced a hTPO derivative where one sugar chain is incorporated into the intact native hTPO (Park et al., J. Biol. Chem., 273: 256-261, 1998), distinctive from the Amgen's partial hTPO derivatives.

15 However, all these derivatives did not show significantly higher levels of hTPO activity.

20 As described above, although various strategies have been employed to develop hTPO derivatives with enhanced biological activity, all failed to obtain the derivatives with higher in vivo hTPO activities than native hTPO.

25 Generally, numerous proteins exist as proteins adorned by oligosaccharide chains in specific position, i.e. glycoproteins. Two types of glycosylation have been found. In O-linked glycosylation, sugar chain is attached to the hydroxyl group of Ser/Thr residue in the glycoprotein. In N-linked glycosylation, sugar chain is attached to the amide group of "Asn-X-Ser/Thr"

(X is any amino acid but proline).

The sugar chain in a glycoprotein exert various effects on the physical, chemical and biological properties such as protein stability and secretion,
5 especially on the biological activity in vivo and pharmacokinetic properties (Jenkins et al., Nature Biotechnological., 14: 975-981, 1996; Liu et al., Act. TIBTECH., 10: 114-120, 1992).

These effects are exemplified by human interferon-
10 γ and glucose transport protein, where amino acid substitution at proper glycosylation site gave rise to the striking decrease in the hTPO activity, suggesting that N-linked sugar chain may have significant effects on the activity of the glycoprotein (Sareneva et al., Biochem. J. 303: 831-840, 1994; Asano et al., FEBS, 15 324: 258-261, 1993).

However, the introduction of additional sugar chains is not always accompanied with an increase in the catalytic activity of the glycoprotein, as
20 described in the precedent art of Amgen INC. and KRIBB (WO 96/25498; Park et al., J. Biol. Chem., 273: 256-261, 1993). Although additional sugar chains were introduced into these hTPO derivatives, the biological activities of the glycoproteins were rather reduced
25 when compared with native hTPO. According to this observation, it is not the number of sugar chains but the specific glycosylation site that is crucial for

elevating its catalytic activity.

We, the inventors of this invention, have prepared various hTPO derivatives and examined their activities.

5 This invention is performed by disclosing that several hTPO derivatives such as derivative wherein Asn is substituted for Arg¹¹¹; derivative wherein Asn is substituted for Thr¹⁵⁵; derivative wherein Asn is substituted for Pro¹¹¹ and Arg¹⁶⁴; and derivative wherein 10 Asn is substituted for Leu¹⁰⁸, Arg¹¹¹ and Arg¹⁶⁴ produce the remarkably higher levels of platelets than native hTPO does, which is not ever observed in the current hTPO derivatives.

15

SUMMARY OF THE INVENTION

It is an object of this invention to provide novel hTPO derivatives that show the higher activities enhancing the platelet production in vivo than native hTPO does.

20

In accordance with the present invention, the foregoing objects and advantages are readily obtained.

The present invention provides novel hTPO derivatives with higher activity inducing the platelet 25 production in vivo. Additional sugar chains are introduced into said hTPO derivatives through

substituting amino acids such as asparagine for amino acids at specific positions in native hTPO.

This invention also provides genes encoding said hTPO derivatives.

5 In addition, this invention provides process of preparing said hTPO derivatives, comprising the step wherein said genes are inserted into appropriate vector; the step wherein a host cell is transfected with said vector; and the step wherein the transfected
10 cells are cultured in appropriate medium.

Further features of the present invention will appear hereinafter.

BRIEF DESCRIPTION OF THE DRAWINGS

15 FIG. 1 depicts PCR-based mutagenesis wherein the cDNAs encoding hTPO derivatives are produced, where

1: primer described by SEQ ID NO: 1;

2: primer described by SEQ ID NO: 2;

N: N-primer;

20 C: C-primer;

S: signal sequence.

FIG. 2 depicts the process of linking the mutated genes to pBlueBac4 vector.

25 FIG. 3 depicts the process of constructing animal expression vectors that the mutated cDNAs are subcloned in pCDT vector.

FIG. 4 presents the result of cell proliferation assay where the activity of M-07e cell proliferation is measured in the presence of hTPO derivatives expressed in animal cells.

5 FIG. 5 presents the *in vivo* activity of native hTPO, which is determined by measuring the number of platelets in mouse blood after treatment with various doses of native hTPO.

FIG 6. presents the *in vivo* activities of various hTPO derivatives, which are determined by measuring the number of platelets in mouse blood after treatment with hTPO derivatives (36 µg/kg) expressed in animal cells.

FIG. 7a and 7b present the *in vivo* activities of various hTPO derivatives, which are determined by measuring the number of platelets in mouse blood after treatment with hTPO derivatives (10 µg/kg) expressed in animal cells.

FIG. 8 depicts the process of constructing the dhfr expression vectors that contain a gene encoding native hTPO or hTPO derivatives.

FIG. 9 presents the result of SDS-PAGE and silver staining with the various fractions obtained in the purification of a hTPO derivative, where

lane M: size marker;
25 lane 1: culture supernatant;
 lane 2: CM-ion exchange affinity column elutes;
 lane 3: phenylsepharose column elutes;

lane 4: hydroxyapatite column elutes;

lane 5: Q cartridge column elutes.

FIG. 10 presents the in vivo activities of native hPO and various hTPO derivatives, which are determined by measuring the number of platelets in mouse blood after treatment with native hTPO or purified hTPO derivatives (10 µg/kg).

FIG. 11 presents the result of SDS-PAGE and western blot analysis with the purified native hTPO and hTPO derivatives, where

lane M: size marker;

lane 1: native hTPO;

lane 2: hTPO derivative 40433;

lane 3: hTPO derivative 40434;

lane 4: hTPO derivative 40449;

lane 5: hTPO derivative 40458;

FIG. 12a and 12b present the result of Western blot analysis, in which the thrombin-digestion pattern of native hTPO (FIG. 12a) or its derivative 40433 (FIG. 20 12b) is shown according to the time after digestion, where

lane M: size marker;

lane 1: Before digestion;

lane 2: 30 minutes after digestion;

lane 3: 1 hour;

lane 4: 2 hours;

lane 5: 3 hours;

lane 6: 4 hours;

lane 7: 6 hours.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

5 Hereinafter, the present invention is described in detail.

The present invention provides novel hTPO derivatives with enhanced activity inducing the platelet production in vivo. Additional sugar chains
10 are introduced into said hTPO derivatives through substituting amino acids such as asparagine for amino acids at specific positions in native hTPO.

To develop novel hTPO derivatives with enhanced activity inducing the platelet production in vivo, a
15 variety of hTPO derivatives were prepared, into which one or more sugar chains are introduced through substituting one or more amino acids at specific positions in a hTPO protein. In result, N-linked glycosylation site "Asn-X-Ser/Thr" (where X is any
20 amino acid but proline) is created at the specific positions.

In a preferred embodiment, site-specific mutagenesis using overlap PCR (Cheng et al., Proc. Natl. Acad. Soc. USA, 91: 5695, 1994) was employed to produce
25 the genes encoding hTPO derivatives with specific amino acids substituted at specific position (see FIG 1).

First, the following primer pairs containing mutated sequences were synthesized chemically. These oligonucleotide primer pairs contain the nucleotide sequences corresponding to the mutated amino acid residues, and extend to the 5' or 3' neighboring sequence to the mutated region in hTPO cDNA.

Table 1. Primer pairs for site-specific mutagenesis

10

Deriv- ative	primer	SEQ ID NO:	Nucleotide sequence
40429	29-N	3	5'-GCTGT GGTGT TGCCC TGTGG-3'
	29-C	4	5'-ACAGG GCAAC ACCAC AGCTC-3'
40430	30-N	5	5'-GGGTT CCGTT TAAAC TCTGC AG-3'
	30-C	6	5'-CTGCA GAGTT TAAAC GGAAC CCAG-3'
40431	31-N	7	5'-AGAGG GTGGA ATTCC CTACA AGCA-3'
	31-C	8	5'-TGCTT GTAGG GAATT CCACC CTCT-3'
40432	32-N	9	5'-GGGCC CGGTT GACGC AGA-3'
	32-C	10	5'-TCTGC GTCAA CCGGG CCC-3'
40433	33-N	11	5'-GGACT AGAGA CGTGT TGCTG GGGAC-3'
	33-C	12	5'-GTCCT CAGCA ACACG TCTCT AGTCC-3'
40434	34-N	13	5'-GAAGC CCAGA TCCGT TAGTT CTGGC-3'
	34-C	14	5'-GCCAG AACTA ACGGA TCTGG GCTTC-3'
40458	58-N	15	5'-AGCTG TGGTG TTTGG GGCCC GC-3'
	58-C	16	5'-GCGGG CCCCC AACAC CACAG CT-3'
	33-N	11	5'-GGACT AGAGA CGTGT TGCTG GGGAC-3'
	33-C	12	5'-GTCCT CAGCA ACACG TCTCT AGTCC-3'
40459	59-N	17	5'-CTAGA GAGGT GCTGT TGACA GCTGT G-3'
	59-C	18	5'-CACAG CTGTC AACAG CAGCA CCTCT CTAG-3'
40460	60-N	19	5'-GGTGG GTGGG GTCCG GTTGA CGCAG AGG-3'
	60-C	20	5'-CCTCT CGCTC AACCG GACCC CACCC ACC-3'
	33-N	11	5'-GGACT AGAGA CGTGT TGCTG GGGAC-3'
	33-C	12	5'-GTCCT CAGCA ACACG TCTCT AGTCC-3'
40461	61-N	21	5'-TCTGC TGGGG GAAGC GTTGG TGGGT GG-3'
	61-C	22	5'-CCACC CACCA ACGCT TCCCC CAGCA GA-3'
	33-N	11	5'-GGACT AGAGA CGTGT TGCTG GGGAC-3'
	33-C	12	5'-GTCCT CAGCA ACACG TCTCT AGTCC-3'
40462	62-N	23	5'-CAGTG TGAGG GTTAG ATTGG TTCTG CTG-3'
	62-C	24	5'-CAGCA GAACC AATCT AACCC TCACA CTG-3'
40463	63-N	25	5'-CAGTG TGAGG TTTAG AGAGG TT-3'
	63-C	26	5'-AACCT CTCTA AACCT CACAC TG-3'
	33-N	11	5'-GGACT AGAGA CGTGT TGCTG GGGAC-3'
	33-C	12	5'-GTCCT CAGCA ACACG TCTCT AGTCC-3'

Overlap PCR was performed wherein the established vector pBlue404 (KOREA APPLICATION NO. 97-7512) containing hTPO cDNA was employed as a template. On the one hand, the oligonucleotide (SEQ ID NO: 1) encoding hTPO signal peptide and one of oligonucleotides (N-primer series in Table 1) encoding mutated sequences were employed as PCR primers. On the other hand, the oligonucleotide (SEQ ID NO: 2) containing hTPO C-terminal ORF and stop codon and one of oligonucleotides (C-primer series in Table 1) encoding mutated sequences were employed as PCR primers.

The overlap PCR products contain the DNA sequences covering from N-terminal signal sequence to mutated region and the DNA sequences covering from mutated region to C-terminal region, respectively.

To obtain the full-length hTPO cDNA sequence containing the target site for amino acid substitution, PCR was done where the two overlap PCR products were employed as a template and two oligonucleotides (SEQ ID NO: 1 and NO: 2) were employed as PCR primers.

Through aforesaid processes, 1078-bp full-length cDNA sequences encoding hTPO derivatives were prepared, which contained a variety of mutated sequences (see FIG. 1).

In a further embodiment, vectors containing the

cDNAs for hTPO derivatives were constructed in order to obtain the expression vectors containing the cDNAs and finally to produce the cell lines transfected with the expression vectors.

5 Particularly, the established vector pBlueBac4 and each cDNA encoding hTPO derivative were digested with *Bgl*II and *Eco*RI restriction enzymes, respectively. Then the two DNA fragments were linked with T4 DNA ligase to construct vectors containing the hTPO derivative cDNA (see FIG. 2).

10 The resulting vectors are illustrated by Table 2, which gives the names of the vectors, the mutated sequences encoding hTPO derivatives, and the amino acid residues modified in accordance with the mutation.

15 The amino acid sequences of hTPO derivatives of this invention are represented by a method where they are described with the amino acid residue substituted and a specified position in the amino acid sequence of native hTPO (SEQ ID NO: 30). For instance, a hTPO derivative of this invention, 40430, may be also referred to as "[Asn¹⁰⁸] hTPO" corresponding to the amino acid sequence described by SEQ ID NO: 30, except for asparagine substituted for the amino acid residue 108.

20
25

Table 2. The substituted amino acid and nucleotide sequences in the vectors containing hTPO derivative

cDNAs

Vectors	substituted amino acid	Mutated nucleotide
pBlue29	R ¹¹¹ → N ¹¹¹	AGG → AAC
pBlue30	I ¹⁶⁴ → N ¹⁶⁴	CTT → AAT
pBlue31	G ¹⁴⁶ G ¹⁵¹ → G ¹⁴⁶ N ¹⁵¹	GGAGGG → CGGAAT
pBlue32	R ¹¹¹ → N ¹¹¹	AGG → AAC
pBlue33	R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵	AGAACCG → AACACG
pBlue34	T ¹⁶³ G ¹⁶⁵ → N ¹⁶³ G ¹⁶⁵	ACTGGT → AACGGA
pBlue58	P ¹⁶⁷ → N ¹⁶⁷	CCC → AAC
	R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵	AGAACCG → AACACG
pBlue59	R ¹⁶² , R ¹⁶⁴ → N ¹⁶² , S ¹⁶⁴	CCC, AGA → AAC, AGC
pBlue60	R ¹⁶³ , A ¹⁶⁷ → N ¹⁶³ , T ¹⁶⁵	AGG, GCC → AAC, ACC
	R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵	AGAACCG → AACACG
pBlue61	T ¹⁶⁹ , V ¹⁶⁷ → N ¹⁶⁹ , S ¹⁶¹	ACA, GTC → AAC, TCC
	R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵	AGAACCG → AACACG
pBlue62	S ¹⁶⁶ , V ¹⁶⁹ → N ¹⁶⁶ , T ¹⁶⁵	TCT, GTC → AAT, ACC
pBlue63	R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵	AGAACCG → AACACG
	V ¹⁶⁵ → N ¹⁶⁵	GTC → AAC

In another preferred embodiment, the expression
5 vectors, which contain the hTPO derivative cDNA sequences, were constructed in order to be introduced into an animal cells.

Specifically, pCDT vector was prepared through the insertion of native hTPO cDNA into the established
10 vector pCDNA3.1. The pCDT and the vectors containing hTPO derivative genes, such as pBlue29, pBlue30, pBlue31, pBlue32, pBlue33, pBlue34, pBlue58, pBlue59, pBlue60, pBlue61, pBlue62 and pBlue63 were digested with *Nhe*I and *Eco*RI enzymes. Then, these fragments
15 were ligated with T4 DNA ligase to obtain animal expression vector containing each hTPO derivative gene

(see FIG. 3 and Table 3).

Table 3. The substituted amino acid and nucleotide sequences in animal expression vectors containing hTPO derivative cDNAs.

Expression vector	Mutated amino acid	Mutated base
p40429	R ¹¹⁷ → N ¹¹⁷	AGG → AAC
p40430	L ¹⁰⁸ → N ¹⁰⁸	CTT → AAT
p40431	G ¹⁴⁶ G ¹⁴⁷ → G ¹⁴⁶ N ¹⁴⁷	GGAGGG → GGGAT
p40432	R ¹⁵³ → N ¹⁵³	AGG → AAC
p40433	R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵	AGAAC → AACACG
p40434	T ¹⁹³ G ¹⁹⁴ → N ¹⁹³ G ¹⁹⁴	ACTGGT → AACGGA
p40435	p40429 + p40431	
p40436	p40429 + p40433	
p40437	p40430 + p40431	
p40438	p40430 + p40433	
p40439	p40431 + p40433	
p40446	p40429 + p40431 + p40433	
p40447	p40430 + p40431 + p40433	
p40449	p40429 + p40430 + p40433	
p40458	P ¹⁵⁷ → N ¹⁵⁷ R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵	CCC → AAC AGAAC → AACACG
p40459	R ¹⁶² , R ¹⁶⁴ → N ¹⁶² , S ¹⁶⁴	CCC, AGA → AAC, AGC
p40460	R ¹⁵³ , A ¹⁵⁵ → N ¹⁵³ , T ¹⁵⁵ R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵	AGG, GCC → AAC, ACC AGAAC → AACACG
p40461	T ¹⁵⁹ , V ¹⁶¹ → N ¹⁵⁹ , S ¹⁶¹ R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵	ACA, GTC → AAC, TCC AGAAC → AACACG
p40462	S ¹⁶⁶ , V ¹⁶⁸ → N ¹⁶⁶ , T ¹⁶⁸	TCT, GTC → AAT, ACC
p40463	R ¹⁶⁴ T ¹⁶⁵ → N ¹⁶⁴ T ¹⁶⁵ V ¹⁶⁸ → N ¹⁶⁸	AGAAC → AACACG GTC → AAC

The scope of this invention includes not only DNA sequences of Table 3 but also other DNA sequences corresponding to the amino acid sequences of Table 3, based on the degeneracy of genetic code. In other

words, all of DNA sequences encoding hTPO derivatives that contain the modified amino acids of Table 3 may be employed as a mutant hTPO gene.

For example, a hTPO derivative, which may be
5 prepared from an expression vector p40433, includes a polypeptide [Asn¹⁶⁴] hTPO, which may be encoded not only by DNA sequence of SEQ ID NO: 31 but also by degenerate DNA sequences.

10 To confirm the insertion of mutated sequences into the vector, the DNA sequencing of PCR products may be employed. Alternatively, if the overlap PCR primers are designed to contain a new restriction site or to delete a wild-type restriction site, the restriction
15 map of the vector may be used to examine mutagenesis. If an expression vector p40433, for example, has a mutated sequence ACACGT in place of wild-type sequence GAACCT, *Afl*III restriction site will be created in p40433. Thus, the digestion of p40433 with *Afl*III can
20 be used to confirm the introduction of mutated sequence.

In a preferred embodiment, hTPO derivatives with two or more amino acid modifications were produced using said expression vectors in order to attach
25 additional sugar chains to the modified amino acid of native hTPO.

Particularly, two kinds of said expression vectors

were digested with appropriate restriction enzymes, and then the resulting fragments were subcloned in said pCDT vector to construct expression vectors which contain the hTPO derivative genes with two or three regions modified. For example, an expression vector p40429 was digested with *Nhe*I and *Bsp*MI enzymes to obtain a DNA fragment involved in the amino acid substitution Arg¹¹⁷ → Asn¹¹⁷. In addition, an expression vector p40431 was digested with *Bsp*MI and *Bsu*36I enzymes to obtain a DNA fragment involved in the amino acid substitution Gly¹⁴⁷ → Asn¹⁴⁷. The resulting two DNA fragments were inserted into the *Bsp*MI-*Bsu*36I site of the pCDT vector, constructing an expression vector p40435 that contained a DNA sequence encoding hTPO with two amino acid substitutions, Arg¹¹⁷ → Asn¹¹⁷ and Gly¹⁴⁷ → Asn¹⁴⁷. In accordance with this procedure, expression vectors such as p40436, p40437, p40438, p40439, p40446, p40447, p40448, and p40449 were constructed (see Table 3).

20

In a further preferred embodiment, animal cell transformants expressing each hTPO derivative was prepared.

Particularly, said expression vectors were transfectected to animal cell line CHO/K-1 through the lipofectamin method, preparing animal cell line expressing each hTPO derivative.

According to the name of the expression vector introduced, the transfected lines were designated CHO K-1/p40429, CHO K-1/p40430, CHO K-1/p40431, CHO K-1/p40432 etc., and CHO K-1/p40433 was deposited in 5 Korean Collection for Type Cultures (; KCTC) on June 17, 1998 (Accesion NO: KCTC 0495BP).

In another preferred embodiment, hTPO derivatives were prepared, by culturing animal cell lines 10 transfected with the expression vector of this invention.

Particularly, the transfected lines were subcultured in a serum-containing medium on large scale, and then transferred to a secretion medium. Cultured 15 medium was concentrated and dialyzed to obtain hTPO derivatives.

A hTPO derivative isolated from CHO K-1/p40433 is polypeptide [Asn¹⁶⁴] hTPO where asparagine is substituted for Arginine¹⁶⁴ in native hTPO sequence.

20 A hTPO derivative isolated from CHO K-1/p40434 is polypeptide [Asn¹⁹³] hTPO where Asn is substituted for threonine¹⁹³ in native hTPO sequence.

A hTPO derivative isolated from CHO K-1/p40449 is polypeptide [Asn¹⁰⁴, Asn¹¹⁷, Asn¹²¹] hTPO where asparagine 25 is substituted for leucine¹⁰⁴, arginine¹¹⁷ and arginine¹²¹ in native hTPO sequence.

A hTPO derivative isolated from CHO K-1/p40458 is

polypeptide [Asn¹⁵, Asn¹⁶] hTPO where asparagine is substituted for proline¹⁵ and arginine¹⁶ in native hTPO sequence.

5 In accordance with the names of expression vectors, the hTPO derivatives expressed in the animal cells were designated 40429 to 40439, 40446, 40447, 40449, and 40458 to 40463, respectively. Their in vitro activities were estimated by measuring proliferation of
10 megakaryocyte leukemia cell line.

In result, derivatives such as 40429, 40430, 40432, 40433, 40434, 40437, 40438, 40439, and the like showed higher levels of biological activity than native hTPO did. No significant relationship between the numbers
15 of additional sugar chains and the in vitro activities was observed, since activities were increased or decreased regardless of the number of sugar chains introduced (see FIG. 4).

20 In a preferred embodiment, hTPO derivatives were administered to mouse and then platelet levels were measured in order to investigate the in vivo biological activities of the hTPO derivatives.

25 In detail, 8-week-old mice were divided into 4 groups according to their weight and then a predetermined concentration of hTPO was subcutaneously administered to mice. After administration, blood was

collected from peripheral vessels of the mice, and platelet levels in blood were measured. While most of derivatives were found to show lower platelet levels than native hTPO did, derivatives 40433, 40434, 40449
5 and 40458 produced platelets at similar or higher efficiencies (see FIG. 6, 7a, or 7b).

These results suggested that hTPO activity in vivo is dependent not on the number of introduced sugar chains but on the specific position of sugar chains.
10 That is, in order to increase the in vivo activity of hTPO, sugar chains should be introduced into specific positions in hTPO, such as amino acid 164, amino acid 193, and so on.

Most notably, platelet levels in 40433-treated
15 group were higher than in native hTPO-treated group, for 2 days from day 3 or 4 after administration, demonstrating that 40433 can be used as a therapeutic agent of thrombocytopenia. The maximum platelet levels in 40433-treated mice were observed on day 5 after
20 administration, reaching 134% of native hTPO activity on day 5, and more than 180% in total.

In another aspect of this invention, in vivo hTPO activities were investigated in purified hTPO
25 derivatives that had produced same or higher platelet levels than native hTPO. To do this, dhfr expression vectors containing the hTPO derivative genes were

constructed, and the resulting vectors were used to prepare cell lines expressing hTPO genes efficiently.

Particularly, *Bam*H I linker was connected to the *Pvu*II-*Sph*I fragment of pSV2-dhfr vector containing dhfr gene. This 1710-bp DNA fragment containing dhfr gene was inserted into pCDT to prepare dhfr expression vector pDCT containing native hTPO gene. Then, the hTPO derivative genes were inserted into pDCT in place of native hTPO gene, constructing dhfr expression vectors pD40433, pD40434, pD40449, and pD40458 (see FIG. 8).

The dhfr expression vectors containing hTPO derivative genes can be readily amplified in the genome of the transfected eukaryotic cells by subculturing the cells. In a preferred embodiment, these vectors were transfected into animal cell line CHO/dhfr(-). The novel transfected cell lines were designated CHO dhfr-/pD40433, CHO dhfr-/pD40434, CHO dhfr-/pD40449, and CHO dhfr-/pD40458, respectively. CHO dhfr-/pD40434, CHO dhfr-/pD40449, and CHO dhfr-/pD40458 were deposited in Korean Collection for Type Cultures (; KCTC) on June 8, 1999 (Accession NO: KCTC 0630BP, KCTC 0631BP, KCTC 0632BP, respectivielty). Other dhfr vectors containing hTPO derivative genes and its transfected cell lines may be obtained according to the said procedure.

The transfected cell lines can be cultured on large scale, and hTPO derivatives can be purified in

accordance with the established methods. Various column chromatography procedures may be employed to purify hTPO derivatives from cell lines that are transfected with dhfr expression vectors containing said hTPO derivative genes. In a preferred embodiment, CM ion-exchange affinity column, phenyl sepharose column, hydroxylapatite column, and so on were employed (see FIG. 9).

To evaluate the in vivo biological activities of the purified hTPO derivatives, platelet levels were measured according to said process, after the derivatives were administered to mice. In 40433-, 40434-, 40449- and 40458-treated groups, the platelet yields reached 177%, 191%, 126% and 179% of native hTPO-treated group, respectively, for 10 days since the administration (see FIG. 10).

To confirm the introduction of additional sugar chains into hTPO derivatives, SDS-PAGE and subsequent Western blot analysis were performed with the purified native hTPO and hTPO derivatives. In result, the molecular weights of derivatives 40433 and 40434 were larger than that of native hTPO. The molecular weights of 40458 with two additional sugar chains and 40449 with three ones were proportionally increased, depending on the number of sugar chains (see FIG. 11).

To examine the stability of hTPO derivatives, native hTPO and a derivative 40433 were treated with

thrombin, and then the protein bands in Western blot were observed in accordance with the digestion time. In result, 40433 was more stable against digestion with thrombin than native hTPO (see FIG. 12). Thus, it was 5 suggested that increased stability due to glycosylation might contribute to the elevation of in vivo hTPO activity.

The pharmaceutical composition containing the hTPO 10 derivatives of this invention may be prepared in a conventional process, and may be formulated alone or in combination with pharmaceutically acceptable carriers, forming agents, diluents and so on. The composition may be used in the formulation of powders, granules, 15 tablets, capsules, injections, and the like.

Particularly, it may be employed in combination with water, phosphate buffer, extroso solution, albumin solution, antioxidants, dextrin and the like. Preferably, it may be administered intravenously or 20 subcutaneously.

The hTPO derivatives may be administered in still less dose than native hTPO, for example, in a dosage range of about 0.01 000 µg/kg/day.

The hTPO derivatives of this invention may be used 25 for the treatment of thrombocytopenia caused by various conditions.

For instance, it may be useful for the treatment

of thrombocytopenia caused by administration of anticancer agents, radiotherapy, bone marrow graft, hepatitis, liver cirrhosis etc. To treat these diseases, the hTPO derivatives may be administered in combination with anticancer agents such as Adriamycin and Cisplatin, and hematopoietic cytokines such as IL-3, MCSF, SCF and EPO.

EXAMPLES

10 Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.

However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may 15 make modifications and improvements within the spirit and scope of the present invention.

Example 1: The PCR-amplification of cDNAs encoding hTPO derivatives

20 To induce site-specific mutagenesis in the gene encoding native hTPO, 12 pairs of oligonucleotides shown in Table 1 were prepared, which contained the specific nucleotide sequences corresponding to the mutated amino acid residues.

The established vector pBlue404 (KOREA PATENT APPLICATION NO. 97-7512) containing hTPO cDNA was employed as a template on which hTPO gene would be amplified.

5 In detail, PCR was carried out, employing 50 ng of pBlue404 as a template. As primers, oligonucleotide (SEQ ID NO: 1) containing the hTPO signal sequence and one of antisense oligonucleotides containing the mutated sequences (N-primers in Table 1) were used.
10 The PCR reactions were performed in 100 µl total volume containing 4 µl of the primer solution (40 pmol/µl) and 1 µl of Pfu (*; Pyrococcus furiosus*) polymerase (2.5 u/µl; Stratagene, Cat. No. 600153). Thermocycle in the PCR was as follows: 90 sec at 94°C for pre-denatuation;
15 35 amplification cycles comprising 40 sec at 94°C for denaturation, 60 sec at 55°C for annealing and 120 sec at 72°C for elongation; and 5 min at 72°C for post-elongation.

Another PCR was performed in accordance with above reaction. As PCR primers, oligonucleotide (SEQ ID NO: 2) containing hTPO C-terminal ORF and stop codon, and one of sense oligonucleotides containing the mutated sequences (C-primers in Table 1) were employed.

Obtained in the PCR were DNA fragments covering from N-terminal hTPO signal sequence to mutated sequence, and DNA fragments from the mutated sequence to hTPO C-terminal.

The PCR products were brought to 1% agarose gel electrophoresis, and then the DNA bands of interest were cut with a razor and eluted in 50 µl of tertiary distilled water with QIAEX II kit (Qiagen, Cat No. 5 20021).

To obtain full-length hTPO cDNAs encoding mutated hTPO, PCR in 100 µl final volume was performed, where two series of PCR products (10 ng, respectively) were employed as templates and two oligonucleotides (SEQ ID 10 NO: 1 and NO: 2) as primers. Thermocycle in the PCR was as follows: 90 sec at 94°C for pre-denatuation; 35 amplification cycles comprising 40 sec at 94°C for denaturation, 60 sec at 58°C for annealing and 120 sec at 72°C for elongation; and 5 min at 72°C for post- 15 elongation.

The PCR products were brought to 1% agarose gel electrophoresis, and then the 1078-bp DNA bands were eluted in 30 µl of tertiary distilled water in accordance with said procedure.

20 To prepare hTPO genes containing two or more regions of mutated DNA sequences, four pairs of primers (the primers 58-N and 58-C, 60-N and 60-C, 61-N and 61-C, 63-N and 63-C) were used in PCR. The full-length cDNAs containing mutated sequence were prepared in 25 accordance with said procedure, and then again brought to site-specific mutagenesis procedure where a primer pair 33-N and 33-C was used.

The modified amino acid and nucleotide sequences in the resulting cDNAs were shown in Table 2.

5 Example 2: The construction of mammalian expression vectors containing hTPO derivative cDNAs and their expression in CHO cells

(2-1) Construction of transfer vectors

The genes encoding hTPO derivatives, which was prepared in Example 1, were subcloned in a commercially 10 available vector pBlueBac4 (Invitrogen, Cat. No. V1995-20), as follows.

The PCR products corresponding to each hTPO derivative were digested with *Bgl*II and *Eco*RI enzymes at 37°C for 3 hours, and then 1068-bp DNA fragment was 15 isolated from the reaction mixture by 1% agarose gel electrophoresis. The 4771-bp DNA fragment was also obtained from pBlueBac4 vector digested with *Bgl*II and *Eco*RI enzymes.

To subclone cDNAs encoding hTPO derivatives in the 20 pBlueBac4 vector, two DNA fragments in a molar ratio of cDNA to vector DNA fragment 4:1 were ligated by incubating them with T4 DNA ligase (NEB, Cat. No. 202S) at 16°C for 16 hours. Then, the ligation mixtures were used to transform *E. coli* TOP10F' strain (Invitrogen, 25 Cat. No. C3030-03) with the resulting transfer vectors.

Electroporation method established already was employed to obtain the *E. coli* transformants. After these transformants were cultured in 50 ml of LB medium (10g Trypton, 5g Yeast extract, 10g NaCl in one liter of water) at 37°C for 18 hours, the transfer vectors were obtained from the cultures with Wizard Midiprep kit (Promega, Cat. No. A7640).

These transfer vectors containing hTPO derivative genes were designated pBlue29, pBlue30, pBlue31, 10 pBlue32, pBlue33, pBlue34, pBlue58, pBlue59, pBlue60, pBlue61, pBlue62, and pBlue63, respectively (see FIG.2).

(2-2) Construction of animal expression vectors

To construct recombinant animal expression vectors containing hTPO derivative genes, pCDT was employed 15 which was prepared by inserting wild-type hTPO gene into a commercially available vector pCDNA3.1 (Invitrogen, Cat. No. 790-20).

Particularly, 5 µg of pCDT vector was digested 20 with EcoRI and NheI enzymes at 37°C for 3 hours, and then 4958-bp DNA fragment was isolated from the reaction mixture by running on 1% agarose gel. The transfer vectors of Example 2-1 were digested with EcoRI and NheI enzymes, and then 1087-bp DNA fragment 25 was also isolated from each restriction mixture.

To subclone cDNA fragments encoding various hTPO derivatives in the pCDT vector, two DNA fragments were

mixed to 3:1 molar ratio and incubated with T4 DNA ligase (NEB, Cat No. 202S) at 16°C for 18 hours. Then, the ligation mixtures were employed to transform *E. coli* TOP10F' strain (Invitrogen, Cat. No. C3030-03) 5 with the resulting expression vectors. Electroporation method established already was employed to obtain the *E. coli* transformants (see FIG. 3). After these transformants were cultured in 50 ml of LB medium at 37°C for 18 hours, the expression vectors were obtained 10 from the cultures with Wizard Midiprep kit (Promega, Cat No. A7640). The animal expression vectors containing hTPO derivative genes were designated p40429, p40430, p40431, p40432, p40433, p40434, p40458, p40459, p40460, p40461, p40462, and p40463, respectively (see 15 FIG. 3). The isolated plasmid DNA was digested with *Nhe*I, *Eco*RI, *Bam*HI and *Bsu*36I enzymes to verify the insertion of the cDNAs. The mutation in the expression vectors was confirmed through restriction mapping and sequencing. The expression vectors were quantified by 20 DNA electrophoresis according to Sambrook et al. (Sambrook et al., Molecular cloning - A laboratory manual, 2nd Ed., Cold spring harbor laboratory press, 1987) and used to transfect CHO/K-1 cell line.

25 (2-3) Expression of hTPO derivative genes in CHO cells
The transfection procedure was carried out according to lipofectamin (Gibco-BRL, Cat. No.

18324012) method. On the day before transfection, CHO/K-1 cells (ATCC CCL-61) were loaded on 6-well microtiter plates at the density of 2×10^5 cells/well. After 24 hours, the cells were once washed with CHO-S-
5 SFM II medium (Gibco-BRL, Cat. No. 12052-098) and 0.8 ml of fresh medium was added to the cells. Meanwhile,
12 µg of each expression vector was added to 600 µl of CHO-S-SFM II medium and then mixed with 600 µl of CHO-S-SFM II medium containing 36 µl of lipofectamin.
10 After the mixture was incubated at room temperature for 30 min, 200-µl aliquots of the mixture per one well were added into the cells in 6-well plates. Then the cells were incubated at 37°C for 5 hours in an atmosphere of 5% CO₂. After the addition of 1 ml of
15 medium containing 10% FBS (Gibco-BRL, Cat. No. 16000-036) to the cells, they were further cultured at 37°C for 24 hours in an atmosphere of 5% CO₂. The medium in the plates was replaced with Ham F-12 (Gibco-BRL, Cat. No. 11059) containing 10% FBS, and then the cells were
20 further cultured at 37°C for 72 hours in an atmosphere of 5% CO₂ to prepare a culture for transient expression.

In addition, after the cells in Ham F-12 medium were cultured for 48 hours, cells in one well of 6-well plates were transferred to medium containing 500 µg/ml
25 of zeocin (Gibco-BRL, Cat. No. R25001) in 100-mm dishes. After the cells were cultured for 7~10 days, zeocin-resistant colonies were identified through microscope.

Cloning cylinder (Bellco, Cat. No. 2090-01010) was used to isolate more than 12 colonies per one hTPO derivative. Gene expression levels were determined by ELISA kit for hTPO (R&D, Cat. No. DTP00), and thereby 5 the cell lines showing the highest expression levels were selected.

Example 3: The construction of mammalian expression vectors containing hTPO derivative cDNAs with two or 10 more modified regions, and their expression in CHO cells

To produce hTPO derivatives where two or more modified amino acid regions, mammalian expression vectors of Example 2 were exploited.

15 In order to construct p40435, the expression vector p40429 was digested with *NheI* and *BspMI* enzymes to isolate 494-bp DNA fragment encoding a substituted amino acid (Arg^{117} to Asn^{117}). Another expression vector p40431 was cut with *BspMI* and *Bsu36I* enzymes to isolate 20 355-bp DNA fragment encoding a substituted amino acid (Gly^{147} to Asn^{147}). Additionally, animal expression vector pCDT containing hTPO cDNA was digested with *NheI* and *Bsu36I* enzymes. The fragments of p40429 and p40431 were inserted into the fragment of pCDT to construct

animal expression vector p40435, which contains cDNA encoding the hTPO derivative with two modified regions (Arg¹¹⁷ to Asn¹¹⁷ and Gly¹⁴⁷ to Asn¹⁴⁷).

Another expression vector p40436 is associated
5 with two amino acid substitutions (Arg¹¹⁷ to Asn¹¹⁷ and Arg¹⁶¹ to Asn¹⁶¹) and was prepared by inserting the 494-bp fragment of p40429 and 593-bp *Bsp*MI-*Eco*RI fragment of p40433 into pCDT.

Expression vectors such as p40437, p40438, and
10 p40439, were prepared in accordance with the above procedure, where two DNA fragments encoding substituted amino acids were isolated from the corresponding vector and inserted into the expression vector pCDT (see Table 3).

15 Other expression vectors such as p40446, p40447, or p40449, were prepared according to a procedure where three DNA fragments encoding substituted amino acids were isolated from the corresponding vector and inserted into pCDT (see Table 3).

20 These eight vectors obtained here were transfected into CHO/K-1 cells in 6-well plates. According to the procedure of Example 2, cultures for transient expression were prepared, and zeocin-resistant colonies were isolated, respectively.

Example 4: Estimation of in vitro activities of hTPO derivatives: M-07e cell proliferation assay

To prepare hTPO derivatives, the transfected cell lines of Example 2 and 3 were cultured in Cell Factory (Nunc, Cat. No. 170009) on 10-liter scale. Each transfected cells (5×10^4 cells/ml) were transferred into Cell Factory containing Ham F-12 medium supplemented with 10% FBS. Cultured for 72 hours, the cells were washed once with PBS and then cultured in ExCell medium (JRH, Cat. No. 14311-10L). After the cells were further cultured at 37°C for 96 hours in an atmosphere of 5% CO₂, supernatants were obtained from the culture. The supernatants were concentrated first with pelicon membrane (Millipore, Cat. No. 42PEL60) and second with minitan membrane (Millipore, Cat. No. 80EL004). After concentration, each sample was brought to dialysis in 1 × TNT buffer (10 mM Tris, 0.15 M NaCl, 0.01% Tween 20, pH 7.4) at 4°C for 30 hours, followed by third concentration with Ultrafree (Millipore, Cat. No. UFV2BGC10). The samples were quantified with ELISA kit three times.

Megakaryocyte leukemia cell line M-07e was maintained in RPMI1640 medium (Gibco-BRL, Cat. No. 22400-089) supplemented with GM-CSF (100 u/ml) and 10% FBS.

To estimate activity, assay medium (RPMI1640 supplemented with 5% FBS) was prepared, and M-07e cells were harvested by centrifugation, then washed with RPMI1640 three times. The cells were resuspended in the 5 assay medium, adjusted to 8×10^4 cells/ml in T-75 flask, and cultured for 24 hours in an atmosphere of 5% CO₂. Again, the cells were harvested and adjusted to 1×10^5 cells/ml. 100 µl aliquots of the cell suspension were added to 96-well plates. Eight-step concentrations 10 (100.0 ~ 0.78125 ng/ml) of standard material (rhTPO, 25 µg) were prepared by serial dilution with RPMI1640 medium, and CHO cell-derived native hTPO was employed as control. Total 11 species of hTPO derivatives (from 40429 to 40439) were prepared at the concentration of 15 1.5625, 6.25 and 25 ng/ml. A 100-µl aliquot of each sample per well was added, adjusting to 200 µl/well. After incubated for 20 hours in an atmosphere of 5% CO₂, the cells were fed with 1 µCi (37 kBq) of ³H-Thymidine 20 and further incubated for 4 hours. Then, cells were harvested using cell harvester equipped with a glass fiber filter, which was washed with PBS seven times.

The filters in which cells were harvested were put 25 in counting vials one by one, and ³H-radioactivities emitted from each sample were measured with a liquid scitilation counter. Riasmart software was used to calculate the half-maximal concentration of standards, control and samples.

All derivatives showed similar patterns of activities stimulating M-07e cell proliferation. At the concentration of 25 ng/ml, 8 species of derivatives 40429, 40430, 40432, 40433, 40434, 40437, 40438 and 5 40439 showed similar or higher activities than native hTPO did, their activities amounting to 117, 135, 120, 131, 97, 121, 166 and 133% of native hTPO activity (see FIG. 4).

10 Example 5: In vivo activities of hTPO derivatives isolated from CHO cells

In vivo hTPO assay was carried out where platelet levels were determined in the mice treated with various hTPO derivatives of this invention, and FIG. 6, 7a and 15 7b give the results. 7-week female Balb/c mice (Charles River, Japan) were adapted in a conditioning room ($24 \pm 1^\circ\text{C}$, 55% R.H., lighting for 12 hours, from 7:00 a.m. to 7:00 p.m.) for a week. The 8-week mice were brought to the assay and kept in the domestication 20 room during the test.

The mice were randomly divided into groups comprising 5 mice on the basis of weights. The groups were specified as groups treated with medium only, treated with native hTPO, treated with each hTPO 25 derivative of this invention, or not treated,

respectively.

Various hTPO derivatives (36 µg/kg or 10 µg/kg) were subcutaneously administered to the mice in single injection, and the blood samples of mice were collected 5 everyday from day 0 (the day of injection) to day 10. Samples were collected from abdominal vena cava within 24 hours after administration. Whole blood in EDTA-treated tube was set on automatic hemocytometer (Cell dyn 3500, Abbott), by which platelet levels in samples 10 were measured. The results were presented in 'mean ± standard error'.

On day 3, native hTPO stimulated an increase in platelet level. The platelet level reached a maximum on day 5 and came to normal level on day 10. All 15 derivatives were found to stimulate an increase in platelet level, and derivatives 40433, 40434, 40449 and 40458 produced equal or higher platelet levels than native hTPO did. Especially, 40433 showed approximately 34% higher maximal in vivo activity of 20 platelet production on day 5 than native hTPO, and 80% or more in total.

Comparative Example 1: in vivo activity of native hTPO

FIG. 5 shows the platelet level in a mouse that 25 was treated with native hTPO derived from animal cells. 7-week female Balb/c mice (Charles River, Japan) were

adapted in a conditioning room ($24 \pm 1^\circ\text{C}$, 55% R.H., lighting for 12 hours, from 7:00 a.m. to 7:00 p.m.) for a week. The 8-week mice were brought to the assay and kept in the domestication room during the test.

5 The mice were randomly divided into groups comprising 5 mice on the basis of weights. The groups were specified as groups treated with medium only, treated with native hTPO, or not treated, respectively. Various concentrations (1, 5 and 10 $\mu\text{g/kg}$) of native
10 hTPO were subcutaneously administered in single injection, and the blood samples of mice were harvested on day 4, 8 and 10 (where day 1 is the day of injection). Sample was harvested from abdominal vena cava within 24 hours after administration. Whole blood
15 in EDTA-treated tube was set on automatic hemocytometer (Cell dyn 3500, Abbott), by which platelet levels in samples were measured. The results were presented in 'mean \pm standard error'. Native hTPO stimulated an increase in platelet level from day 4. The platelet
20 level reached a maximum on day 8 and came down to 80% of the maximal value on day 10.

Example 6: Construction of dhfr expression vectors containing hTPO derivative cDNAs, and selection of mammalian cell lines expressing them

(6-1) Construction of dhfr expression vectors
5 containing hTPO derivative cDNAs

According to the result of Example 5, dhfr expression vectors were constructed, which corresponding to the derivatives 40433, 40434, 40449 and 40458.

10 At first, *Bam*HI linker was inserted into pSV-dhfr (ATCC 37146) containing dhfr gene. To prepare *Bam*HI linker, two oligonucleotides (SEQ ID NO: 27 and NO: 28) were phosphorylated and then annealed to hybridize with each other. Particularly, T4 polynucleotide kinase
15 (NEB, Cat. No. 201S) was used in the phosphorylation reaction at 37°C for 3 hours. In the annealing reaction, the equimolar oligonucleotides were mixed and placed at 94°C for 2 min, then the mixture was stepwisely cooled down from 65°C to 37°C with the temperature decreased
20 by 0.2°C per 30 sec. The vector pSV2-dhfr was restricted with *Pvu*II and *Sph*I enzymes, then the *Bam*HI linker was connected with the fragment of pSV2-dhfr. The resulting vector was digested with *Bam*HI enzyme in order to prepare the 1710-bp fragment containing dhfr
25 gene.

After the expression vector pCDT containing wild-type hTPO gene was digested with *Bgl*II enzyme, the 1710-bp fragment were inserted into the pCDT. The resulting dhfr expression vector expressing native hTPO 5 was designated pDCT (see FIG. 8).

To dhfr expression vectors corresponding to 5 derivatives, two oligonucleotides (SEQ ID NO: 29 and NO: 2) were employed as PCR primers. Except for primers, the PCR was performed under the same condition 10 as in Example 1. Amplified DNA sequences encoding hTPO derivatives were cut with *Kpn*I and *Eco*RI enzymes, and then inserted into the *Kpn*I-*Eco*RI site of the pDCT vector. The resulting vectors were designated pD40433, pD40434, pD40449 and pD40458, respectively.

15

(6-2) Transfection into CHO/dhfr(-) cell line and gene amplification

The dhfr expression vectors of Example 6-1 were transfected into animal cell line CHO/dhfr(-) (ATCC 20 CRL-9096) according to the transfection procedure of Example 2. IMDM medium (Gibco-BRL, Cat. No. 12200-036) was used for the transfection, and IMDM medium supplemented with 10% dialyzed FBS (Gibco-BRL, Cat. No. 26300-061) for subsequent culture.

25 To select transformed line, the cells were added to 96-well microtiter plates (1×10^3 cells/well) in 48 hours after transfection, and cultured for 10-14 days

in medium containing 500 µg/ml zeocin. Zeocin-resistant colonies were isolated, and the 10-20 cell lines producing higher expression levels were selected by ELISA quantification.

5 The selected cell lines were subcultured in medium containing 20 nM MTX (Methotrexate, Sigma, Cat. No. M8407) to amplify hTPO gene. In detail, the cells were cultured in T-25 flask until flask was saturated with the cells. One-fifth of the saturated cells were
10 subcultured, then 1/10 and 1/15, successively. Amplification finished when T-25 flask was saturated with cells in 3-4 days after the 1/15 subculture. Cell lines producing highest expression levels were selected by ELISA from amplified cell lines in 20 nM MTX. The
15 cell lines were used to prepare samples for in vivo hTPO assay.

Example 7: Expression of native hTPO and derivatives

thereof in CHO/dhfr(-) cells, and their purification

20 To prepare native hTPO and derivatives thereof, the cell lines of Example 6 were cultured in Cell Factory (Nunc, Cat. No. 170069) on 4-liter scale. Each cell line (5×10^4 cells/ml) was transferred into Cell Factory containing IMDM medium supplemented with 10%
25 FBS. Cultured for 72 hours, the cells were washed once

with PBS and then cultured in DMEM/Ham F-12 medium. After the cells were further cultured at 37°C for 96 hours in an atmosphere of 5% CO₂, supernatants obtained from the culture were brought to purification steps.

5 After XK26/20 column (Amersham-pharmacia, Cat. No. 18-1000-72) was filled with 50 ml of CM Affi-Gel blue resin (Bio-Rad, Cat. No. 153-7304), the column was washed with buffer A (10 mM sodium phosphate, 150 mM sodium chloride, pH 7.4) overnight. 4-liter of the
10 culture supernatants was loaded and passed through the column with the flow rate of 5 ml/min, and was monitored by spectrophotometry at UV wavelength 280nm. After the whole culture supernatant was distributed throughout the column, the column was washed with
15 buffer B (10 mM sodium phosphate, 2 M urea, pH 7.4) until the UV absorption dropped to basal level. Bound proteins including hTPO were eluted with buffer C (10 mM sodium phosphate, 2 M urea, 1 M sodium chloride, pH 7.4), and this fraction was applied to subsequent
20 phenylsepharose column chromatography. XK26/20 column was filled with 50 ml of phenylsepharose CL4B resin (Sigma, Cat. No. P7892) and then washed with buffer C overnight. The fraction eluted from CM Affi-Gel blue column was applied to the pheylsepharose column with
25 flow rate of 3 ml/min and monitored by spectrophotometry at UV wavelength 280 nm. After the whole culture supernatant was distributed throughout

the column, the column was washed with buffer C until the UV absorption dropped to basal level. Proteins bound to resin were eluted with buffer B and this fraction was applied to subsequent hydroxylapatite column chromatography. XK16/20 column (Amersham-pharmacia, Cat. No. 18-8773-01) was filled with 10 ml of hydroxylapatite resin (Bio-Rad, Cat. No. 130-0420) and washed with buffer D (10 mM sodium phosphate, 2 M urea, pH 6.8) overnight. The fraction eluted from the pheylsepharose column was adjusted to pH 6.8 with 5 N HCl and then applied to hydroxylapatite column with flow rate of 3 ml/min. Since hTPO is not bound to hyroxylapatite resin, the unbound fraction was reserved. The column was washed with buffer D until the UV absorption dropped to basal level. Then, impure proteins bound to resin were eluted with buffer E (0.5 M sodium phosphate, 2 M urea, pH 6.8). The obtained hTPO fraction was concentrated to 10-ml volume using Econo-Pac Q cartridge (Bio-Rad, Cat. No. 732-0021), and then dialyzed in 10 mM sodium phosphate for 24 hours to eliminate salts and urea. Each fraction in the purification steps was visualized through SDS-PAGE and silver staining (see FIG. 9), where Silver-stain Plus kit (Bio-Rad, Cat. No. 161-0449) was used in accordance with the manufacturer instruction.

In vivo hTPO assay was performed with the purified hTPO derivatives (dose: 10 µg/kg) according to the

method of Example 5. All derivatives were found not only to stimulate an increase in platelet level, but also to produce higher platelet levels than native hTPO did. Particularly, 40433, 40434, 40449, and 40458 showed 77%, 91%, 26%, and 79% higher activities for total 10 days after administration than native hTPO, respectively (see FIG. 10).

Example 8: Characterization of hTPO derivatives:
10 verifying the introduction of sugar chains and
examining the stability of hTPO derivatives

To investigate whether additional sugar chains were introduced into the hTPO derivatives, SDS-PAGE and Western blot analysis was performed. If sugar chains 15 are introduced, the molecular weights of hTPO derivatives will be heavier than that of native hTPO.

Purified native hTPO and derivatives thereof were loaded into wells in 10 20% gradient tricine polyacrylamide gel (Novex, Cat. No. EC66252), which was 20 run at a voltage of 10 V/cm. After electrophoresis, the proteins fractionated on the gel were transferred onto a nitrocellulose filter. The filter was incubated for 1 hour in TBS (pH 7.5) containing 5% non-fat dried milk, and then further incubated for 18 hours with goat 25 anti-hTPO polyclonal antibody (R&D system, Cat. No. AB-

288-NA) diluted in TBS (1:1000). The filter was subsequently incubated for 2 hours with a secondary antibody, alkaline phosphatase-conjugated anti-goat IgG (Sigma, Cat. No. A4187) diluted in TBS (1:10000). The 5 coloring substrate BCIP/NBT (Sigma, Cat. No. B5655) was used for detecting hTPO band. In result, molecular weights of purified hTPO derivatives were heavier than that of native hTPO, depending on the number of sugar chains introduced (FIG. 11).

10 To evaluate the stability of hTPO derivatives, native hTPO and a hTPO derivative 40433 were digested with Thrombin, and then the time-dependent digestion patterns were observed. The hTPO derivative (50 µg/ml) was treated with Thrombin (5 units/ml, Sigma, Cat. No. T6759) at 37°C for 0.5, 1, 2, 3, 4, or 6 hours. Then, 15 SDS-PAGE and Western blot analysis was performed to observe the digestion patterns. Native hTPO was strikingly degraded in 30 min after treatment with Thrombin, while the derivative 40433 was digested in 4 hours (see FIG. 12). This result verified that the 20 derivative 40433 is more stable than native hTPO, which can be explained from the sugar chain introduced.

INDUSTRIAL APPLICABILITY

25 As shown above, the hTPO derivatives of this invention induce the production of platelet precursor

cells in vivo, and thus are useful for the treatment of thrombocytopenia associated with anticancer therapies or bone marrow graft. Especially, the hTPO derivatives 40433, 40434, 40449 and 40458 show significantly higher 5 efficacy inducing platelet production than native hTPO, providing various advantages. Since low dose of hTPO derivatives shows similar efficacy to native hTPO, small dose of hTPO can be infrequently administered to the patients suffering from thrombocytopenia.

10 Therefore, use of derivatives of this invention will reduce the cost of treating the disease and will elevate the welfare of patients as well as the safety of the drug, with the inclusion of impure proteins excluded, owing to the small dose used.

15

Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for 20 carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.

25

PCT

9FPO-04-08

Original (for SUBMISSION) - printed on 30.06.1999 12:00:19 PM

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.84 (updated 01.06.1999)
0-2	International Application No	PCT/KR 99/00347
0-3	Applicant's or agent's file reference	9FPO-04-08
1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	19, 48
1-2	line	4, 25
1-3	Identification of Deposit	
1-3-1	Name of depositary institution	Korean Collection for Type Cultures
1-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
1-3-3	Date of deposit	17 June 1998 (17.06.1998)
1-3-4	Accession Number	KCTC 0495BP
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications	
	These indications will be submitted to the International Bureau later	
2	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
2-1	page	22, 49
2-2	line	21, 2
2-3	Identification of Deposit	
2-3-1	Name of depositary institution	Korean Collection for Type Cultures
2-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
2-3-3	Date of deposit	08 June 1999 (08.06.1999)
2-3-4	Accession Number	KCTC 0630BP
2-4	Additional Indications	NONE
2-5	Designated States for Which Indications are Made	all designated States
2-6	Separate Furnishing of Indications	
	These indications will be submitted to the International Bureau later	
3	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
3-1	page	22, 49
3-2	line	21, 6


PCT

9FPO-04-08

Original (for SUBMISSION) - printed on 30.06.1999 12:00:19 PM

3-3	Identification of Deposit	
3-3-1	Name of depositary institution	
3-3-2	Address of depositary institution	
3-3-3	Date of deposit	
3-3-4	Accession Number	
3-4	Additional Indications	
3-5	Designated States for Which Indications are Made	
3-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	
4	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
4-1	page	22, 49
4-2	line	22, 10
4-3	Identification of Deposit	
4-3-1	Name of depositary institution	
4-3-2	Address of depositary institution	
4-3-3	Date of deposit	
4-3-4	Accession Number	
4-4	Additional Indications	
4-5	Designated States for Which Indications are Made	
4-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	

FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	YES
0-4-1	Authorized officer	Lee, Seung Jong 

FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the International Bureau on:	
0-5-1	Authorized officer	

What is claimed is

1. Human thrombopoietin derivative which derived from human thrombopoietin (hTPO) described by SEQ ID NO: 30; which has at least one additional N-linked glycosylation site; and which is selected from the group comprising:
 - 5 [Asn¹⁰⁸] hTPO;
 - [Asn¹¹⁷] hTPO;
 - 10 [Asn¹⁴⁷] hTPO;
 - [Asn¹⁵²] hTPO;
 - [Asn¹⁶⁴] hTPO;
 - [Asn¹⁹³] hTPO;
 - [Asn¹¹⁷, Asn¹⁴⁷] hTPO;
 - 15 [Asn¹¹⁷, Asn¹⁶⁴] hTPO;
 - [Asn¹⁰⁸, Asn¹⁴⁷] hTPO;
 - [Asn¹⁰⁸, Asn¹⁶⁴] hTPO;
 - [Asn¹⁴⁷, Asn¹⁶⁴] hTPO;
 - [Asn¹¹⁷, Asn¹⁴⁷, Asn¹⁶⁴] hTPO;
 - 20 [Asn¹⁰⁸, Asn¹⁴⁷, Asn¹⁶⁴] hTPO;
 - [Asn¹⁰⁸, Asn¹¹⁷, Asn¹⁶⁴] hTPO;
 - [Asn¹⁵⁷, Asn¹⁶⁴] hTPO;
 - [Asn¹⁶², Ser¹⁶⁴] hTPO;
 - [Asn¹⁶², Thr¹⁶⁴] hTPO;
 - 25 [Asn¹¹⁷, Ser¹⁶², Asn¹⁶⁴] hTPO;
 - [Asn¹¹⁷, Thr¹⁶², Asn¹⁶⁴] hTPO;

- [Asn¹⁵⁴, Ser¹⁶¹, Asn¹⁶⁴] hTPO;
[Asn¹⁶⁴, Thr¹⁶⁵, Asn¹⁶⁴] hTPO;
[Asn¹⁶⁶, Ser¹⁶⁷] hTPO;
[Asn¹⁶⁶, Thr¹⁶⁷] hTPO; and
5 [Asn¹⁶⁶, Asn¹⁶⁷] hTPO.
2. The human thrombopoietin derivative of claim 1 which is [Asn¹⁵⁴] hTPO, [Asn¹⁶¹] hTPO, [Asn¹⁶⁶, Asn¹⁶⁷, Asn¹⁶⁸] hTPO, or [Asn¹⁶⁷, Asn¹⁶⁸] hTPO.
- 10
3. Recombinant gene encoding human thrombopoietin derivative of claim 1.
4. Recombinant gene encoding human thrombopoietin derivative of claim 2.
- 15
5. Eukaryotic expression vector containing the recombinant gene of claim 3.
- 20
6. The eukaryotic expression vector of claim 5 which is p40433, p40434, p40449, p40458, pD40433, pD40434, pD40449, or pD40458.
- 25
7. Mammalian cell line CHO K-1/p40433 (Accession NO: KCTC 0495BP) transfected with the expression vector p40433 of claim 6.

8. Mammalian cell line CHO dhfr-/pD40434 (Accession
NO: KCTC 0630BP) transfected with the expression
vector pD40434 of claim 6.
- 5 9. Mammalian cell line CHO dhfr-/pD40449 (Accession
NO: KCTC 0631BP) transfected with the expression
vector p40449 of claim 6.
- 10 10. Mammalian cell line CHO dhfr-/pD40458 (Accession
NO: KCTC 0632BP) transfected with the expression
vector p40458 of claim 6.
- 15 11. Process of preparing the human thrombopoietin
derivative of claim 1 wherein a mammalian cell line
containing the recombinant gene of claim 3 is used
to obtain the human thrombopoietin derivative of
claim 1.
- 20 12. Pharmaceutical composition containing the human
thrombopoietin derivative of claim 1 which is used
for the treatment of thrombocytopenia.

FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5



5/12

FIG. 6




FIG. 7a




FIG. 7b




FIG. 8




FIG. 9






FIG. 10



10/12

FIG. 11



11/12

FIG. 12a





FIG. 12b



SEQUENCE LISTING

<110> Daewoong Pharmaceutical Co., Ltd.

<120> A novel human thrombopoietin mutoein

<130> 9fpo-04-08

<150> KR 98-25935

<151> 1998-06-30

<150> KR 99-25143

<151> 1999-06-29

<160> 34

<170> KOPATIN 1.0

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> BglII-tagged primer corresponding to the N terminal sequence of hTPO protein

<400> 1

gaagatctat ggagctgact gaa

23

<210> 2

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> EcoRI-tagged primer corresponding to the C terminal sequence of hTPO protein

<400> 2

atgaattctc acccttcctg agac

24

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligodeoxynucleotide primer 29-N

<400> 3
gctgtggtgt tgccctgtgg

20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligodeoxynucleotide primer. 29-C

<400> 4
acagggcaac accacagctc

20

<210> 5
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligodeoxynucleotide primer. 30-N

<400> 5
gggttccgtt taaactctgc ag

22

<210> 6
<211> 24
<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligodeoxynucleotide primer 30-C

<400> 6

ctgcagagg taaacggaac ccag

24

<210> 7

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 31-N

<400> 7

agaggggtgga attccctaca agca

24

<210> 8

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 31-C

<400> 8

tgcttgtagg gaattccacc ctct

24

<210> 9

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 32-N

<400> 9
gggccccgtt gacgcaga 18

<210> 10
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 32-C

<400> 10
tctgcgtcaa ccggggccc 18

<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 33-N

<400> 11
ggactagaga cgttttgctg gggac 25

<210> 12
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 33-C

<400> 12
gtccccagca acacgtctct agtcc 25

<210> 13

<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 34-N

<400> 13
gaagcccaaga tccgttagtt ctggc

25

<210> 14
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 34-C

<400> 14
gccagaacta acggatctgg gcttc

25

<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 58-N

<400> 15
agctgtggtg tttggggccc gc

22

<210> 16
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> primer 58-C

<400> 16

gcggggccca aacaccacag ct

22

<210> 17

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 59-N

<400> 17

ctagagaggt gctgttgaca gctgtg

26

<210> 18

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 59-C

<400> 18

cacagctgtc aacagcagca cctctctag

29

<210> 19

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 60-N

<400> 19

ggtgtgggtggg gtcccggttga cgcgagg

28

<210> 20
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 60-C

<400> 20
cctctgcgtc aaccggaccc cacccacc

28

<210> 21
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 61-N

<400> 21
tctgctgggg gaagcggtgg tgggtgg

27

<210> 22
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 61-C

<400> 22
ccacccacca acgtttcccc cagcaga

27

<210> 23
<211> 28
<212> DNA
<213> Artificial Sequence

<220>

<223> primer 62-N

<400> 23

cagtgtgagg gtttagattgg ttcttgctg

28

<210> 24

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 62-C

<400> 24

cagcagaacc aatctaacc tcacactg

28

<210> 25

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 63-N

<400> 25

cagtgtgagg ttttagagagg tt

22

<210> 26

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 63-C

<400> 26

aacctctcta aacctcacac tg

22

<210> 27

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligodeoxynucleotide 1 of BamHI linker

<400> 27

cgcggatccg catg

14

<210> 28

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligodeoxynucleotide 2 of BamHI linker

<400> 28

cggatccg

10

<210> 29

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> KpnI-tagged primer corresponding to the N terminal sequence of hTP0 protein

<400> 29

gggttaccgc caccatggag ctgactgaat tg

32

<210> 30

<211> 332

<212> PRT

<213> Homo sapiens

<400> 30

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu
1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val
20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu
35 40 45

Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Leu
50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln
65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln
85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu
100 105 110

Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe
115 120 125

Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu
130 135 140

Val Gly Gly Ser Thr Leu Cys Val Arg Arg Ala Pro Pro Thr Thr Ala
145 150 155 160

Val Pro Ser Arg Thr Ser Leu Val Leu Thr Leu Asn Glu Leu Pro Asn
165 170 175

Arg Thr Ser Gly Leu Leu Glu Thr Asn Phe Thr Ala Ser Ala Arg Thr
180 185 190

Thr Gly Ser Gly Leu Leu Lys Trp Gln Gln Gly Phe Arg Ala Lys Ile

195	200	205
Pro Gly Leu Leu Asn Gln Thr Ser Arg Ser Leu Asp Gln Ile Pro Gly		
210	215	220
Tyr Leu Asn Arg Ile His Glu Leu Leu Asn Gly Thr Arg Gly Leu Phe		
225	230	235
Pro Gly Pro Ser Arg Arg Thr Leu Gly Ala Pro Asp Ile Ser Ser Gly		
245	250	255
Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Leu Gln Pro Gly Tyr Ser		
260	265	270
Pro Ser Pro Thr His Pro Pro Thr Gly Gln Tyr Thr Leu Phe Pro Leu		
275	280	285
Pro Pro Thr Leu Pro Leu Pro Val Val Gln Leu His Pro Leu Leu Pro		
290	295	300
Asp Pro Ser Ala Pro Thr Pro Thr Pro Thr Ser Pro Leu Leu Asn Thr		
305	310	315
Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Glu Gly		
325	330	

<210> 31
<211> 996
<212> DNA
<213> Artificial Sequence

<220>
<223> cDNA sequence encoding hTPO murein 40433
<400> 31
agcccggtc ctcttgctt tgacctccga gtcctcagta aactgcttcg tgactccat 60
gtccttcaca gcagactgag ccagtgcacca gaggttcacc ctttgctac acctgtcctg 120
ctgcctgctg tggacttag cttgggagaa .tggaaaaccc agatggagga gaccaaggca 180

caggacattc tgggagcagt gacccttctg ctggaggag tcatggcagc acggggacaa	240
ctgggaccca cttgcctctc atccctcctg gggcagcttt ctggacaggt ccgtctcctc	300
cttggggccc tgcagagcct ctttggAACc cagtttcctc cacagggcag gaccacagct	360
cacaaggatc ccaatgccat cttcctgagc ttccaacacc tgctccgagg aaaggtgcgt	420
ttcctgatgc ttgttaggagg gtccaccctc tgcgtcaggc gggccccacc caccacagct	480
gtccccagca acacgtctct agtcctcaca ctgaacgagc tcccaaacag gacttctgga	540
ttgttggaga caaacttcac tgcctcagcc agaactactg gctctggct tctgaagtgg	600
cagcaggat tcagagccaa gattccctggt ctgctgaacc aaacctccag gtccctggac	660
caaatacccg gatacctgaa caggatacac gaactcttga atgaaactcg tggactcttt	720
cctggaccct cacgcaggac cctaggagcc ccggacattt cctcaggaac atcagacaca	780
ggctccctgc cacccaaacct ccagccctgga tatttcctt ccccaaccca tcctcctact	840
ggacagtata cgctcttccc tcttccaccc accttgccca cccctgtggt ccagctccac	900
ccccctgtttc ctgacccttc tgctccaacg cccaccccta ccagccctct tctaaacaca	960
tcctacaccc actcccaagaa tctgtctcag gaaggg	996

<210> 32

<211> 996

<212> DNA

<213> Artificial Sequence

<220>

<223> cDNA sequence encoding hTPO mutein 40434

<400> 32

agcccggttc ctccgtttg tgacccctga gtcctcagta aactgcttcg tgactccat 60

gtccttcaca gcagactgag ccagtgcaca gaggttcacc ctttgcctac acctgtcctg	120
ctgcctgctg tggactttag cttggggagaa tggaaaaccc agatggagga gaccaaggca	180
caggacattc tgggagcagt gaccctctg ctggagggag tcatggcagc acggggacaa	240
ctggaccca ctgcctctc atccctctg gggcagctt ctggacaggt ccgtctcctc	300
cttggggccc tgcagagcct ctttggAACc cagtttcctc cacagggcag gaccacagct	360
cacaaggatc ccaatgccat cttcctgagc ttccaacacc tgctccgagg aaaggtgcgt	420
ttcctgatgc ttgttaggagg gtccaccctc tgcgtcaggc gggccccacc caccacagct	480
gtccccagca gaacctctct agtcctcaca ctgaacgagc tcccaaacag gacttctgga	540
ttgttgaga caaacttcac tgcctcagcc agaactaacg gatctggct tctgaagtgg	600
cagcagggat tcagagccaa gattccttgtt ctgctgaacc aaacctccag gtccctggac	660
caaatccccg gatacctgaa caggatacac gaactcttga atgaaactcg tggactcttt	720
cctggaccct cacgcaggac cctaggagcc ccggacattt cctcaggaac atcagacaca	780
ggctccctgc cacccaaacct ccagcctgga tattctcctt ccccaaccca tcctcctact	840
ggacagtata cgctttccc tttccaccc acttggcca cccctgttgtt ccagctccac	900
ccctgttttc ctgacccttc tgctccaacg cccaccccta ccagccctct tctaaacaca	960
tcctacaccc actccccagaa tctgtctcag gaaggg	996

<210> 33
<211> 996
<212> DNA
<213> Artificial Sequence

<220>
<223> cDNA sequence encoding hTPO mutein 40449

<400> 33
 agcccggctc ctccctgcttg tgacacctcg aactgcttcg tgactccat 60
 gtccttcaca gcagactgag ccagtgcacc gaggttcacc cttgcctac acctgtcctg 120
 ctgcctgctg tggactttag cttggagaaa tggaaaaccc agatggagga gaccaaggca 180
 caggacattc tgggagcagt gacccttctg ctggagggag tgcgtgcgc acggggacaa 240
 ctgggaccca cttgcctc tc atccctctg gggcagctt ctggacaggt ccgtctcctc 300
 cttggggccc tgcagagttt aaacggaaacc cagcttcctc cacagggcaa caccacagct 360
 cacaaggatc ccaatgccat cttcctgagc ttccaacacc tgctccgagg aaagggtgcgt 420
 ttccctgatgc ttgttaggagg gtccaccctc tgcgtcaggc gggccccacc caccacagct 480
 gtccccagca acacgtctct agtcctcaca ctgaacgagc tcccaaacag gacttctgga 540
 ttgttggaga caaacttcac tgcctcagcc agaactactg gctctggct tctgaagtgg 600
 cagcagggat tcagagccaa gattcctggc tgcgtgaacc aaacctccag gtccctggac 660
 caaatccccg gatacctgaa caggatacac gaactttga atgaaactcg tggactcttt 720
 cctggaccct cacgcaggac cctaggagcc ccggacattt cctcaggaac atcagacaca 780
 ggctccctgc cacccaaacct ccagcctgga tatttcctt ccccaaccca tcctcctact 840
 ggacagtata cgctcttccc tcttccaccc acctgcccc cccctgtggt ccagctccac 900
 cccctgcttc ctgacccttc tgctccaacg cccaccccta ccagccctct tctaaacaca 960
 tcctacaccc actccccagaa tctgtctcag gaaggg 996

<210> 34

<211> 996

<212> DNA

<213> Artificial Sequence

<220>

<223> cDNA sequence encoding hTPO mutein 40458

<400> 34

agccccggctc	ctcctgcttg	tgacacctcgaa	gtcctcagta	aactgcattcg	tgactcccat	60
gtccttcaca	gcagactgag	ccagtgccca	gaggttcacc	ctttgcctac	acctgtcctg	120
ctgcctgctg	tggactttag	cttggggagaa	tggaaaaccc	agatggagga	gaccaaggca	180
caggacattc	tgggagcagt	gacccttctg	ctggaggagg	tgatggcagc	acggggacaa	240
ctggggaccca	cttgcctctc	atcccctcctg	gggcagcttt	ctggacaggt	ccgtctcctc	300
cttggggccc	tgcagagcct	ccttggaaacc	cagcttcctc	cacagggcag	gaccacagct	360
cacaaggatc	ccaatgccat	cttcctgagc	ttccaacacc	tgctccgagg	aaaggtgcgt	420
ttcctgatgc	ttttaggagg	gtccaccctc	tgcgtcaggc	gggccccaaa	caccacagct	480
gtccccagca	acacgtctct	agtccctcaca	ctgaacgagc	tcccaaacag	gacttctgga	540
tttgttggaga	caaacttcac	tgcctcagcc	agaactactg	gctctggct	tctgaagtgg	600
cagcagggat	tcaagagccaa	gattcctgg	ctgctgaacc	aaacctccag	gtccctggac	660
caaatccccg	gatacctgaa	caggatacac	gaactcttga	atggaactcg	tggactcttt	720
cctggaccct	cacgcaggac	cctaggagcc	ccggacattt	cctcaggaac	atcagacaca	780
ggctccctgc	cacccaaacct	ccagcctgga	tattctcctt	ccccaaaccc	tcctcctact	840
ggacagtata	cgtctttccc	tcttccaccc	accttgccca	cccctgtggt	ccagctccac	900
ccctgttttc	ctgacccttc	tgctccaacg	cccaccccta	ccagccctct	tctaaacaca	960
tcctacaccc	actccccagaa	tctgtctcag	gaaggg			996

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00347

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 12 N 15/19, 15/79, 5/10, A 61 K 38/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 12 N 15/19, 15/79, 5/10, A 61 K 38/19

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, CAS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 25498 A2 (AMGEN INC.) 22 August 1996 (22.08.96), page 1; claims 1, 2, 4, 5, 7-21.	1 - 12
A	WO 96 17062 A1 (ZYMOGENETICS, INC.) 6 June 1996 (06.06.96), claims 1, 6-9, 19, 21, 23, 26, 28.	1, 3, 5, 7-12
A	WO 95 18858 A1 (GENENTECH, INC.) 13 July 1995 (13.07.95), pages 15-17, claims 1-4, 22, 24-26, 29-31, 36, 37, 40.	1, 3, 5, 11, 12
A	EP 0 668 352 A1 (KIRIN BREWERY COMPANY, LTD.) 23 August 1995 (23.08.95), claims 1, 17, 22, 30, 31, 33.	1, 3, 11, 12
A	Hoffman et al. Peptide, Disulfide, and Glycosylation Mapping of Recombinant Human Thrombopoietin Ser 1 to Arg 246, Biochemistry 1996, 35 (47), 14849-14861 (Eng.). Columbus, Ohio, USA: Chemical abstracts, Vol. 126, No. 6, 10 February 1997, page 80, left column, the abstract no. 70279s.	1

Further documents are listed in the continuation of Box C.

See patent family annex.

- * Special categories of cited documents:
- „A“ document defining the general state of the art which is not considered to be of particular relevance „T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- „E“ earlier application or patent but published on or after the international filing date „X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- „L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) „Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- „O“ document referring to an oral disclosure, use, exhibition or other means „&“ document member of the same patent family
- „P“ document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search	Date of mailing of the international search report
6 October 1999 (06.0.99)	05 November 1999 (05.11.99)
Name and mailing address of the ISA/AT Austrian Patent Office Kohlmarkt 8-10; A-1014 Vienna Facsimile No. 1/53424/200	Authorized officer Mosser Telephone No. 1/53424/437

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 99/00347

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report	Datum der Veröffentlichung Publication date	Mitglied(er) der Patentfamilie Patent family member(s)	Datum der Veröffentlichung Publication date
Document de brevet cité dans le rapport de recherche	Date de publication	Membre(s) de la famille de brevets	Date de publication
WO A2 9625498	22-08-1996	AU A1 49946/96 AU B2 691410 CA AA 2209298 CN A 1192453 EP A2 B11064 JP T2 11500904 NZ A 303588 US A 5756083 WO A3 9625498 US A 5696250	04-09-1996 14-05-1998 22-08-1996 20-05-1998 10-12-1997 26-01-1999 25-02-1999 26-05-1998 20-03-1997 09-12-1997
WO A1 9617062	06-06-1996	AU A1 41631/96	19-06-1996
WO A1 9519856	13-07-1995	AU A1 15146/95 AU B2 704266 BE AF 1009021 BG A 100693 CA AA 2178482 CN A 1141061 CZ A3 9801922 DE A1 19500030 DK A 1491/94 ES A1 738323 ES AA 2114786 ES BA 2114786 ES AO 982723 ES A 982723 FI A1 2714670 FI B1 2714670 FI AO 9425834 FI A1 22085448 FI B2 22085448 FI B 10020005 FI A1 941020 FI AO 9801805 FI A2 75657 FI A1 950002 FI B 72517 FI A0 112184 FI A0 950002 FI A1 TD 950002 FI B1 1283770 FI T 9508262 FI A2 10113184 FI A 88573 FI AB 11632 FI A0 9500010 FI A0 952783 FI A 952783 FI A 278725 FI A 101627 FI A1 101627 FI A 47030 FI A 9420079 FI A3 875/96 FI A 5830647 FI A 9408487 FI A 96118 LT B 4120 ZA A 9410355	01-08-1995 15-04-1999 01-10-1996 30-01-1998 13-07-1995 22-01-1997 14-05-1997 04-07-1995 04-07-1995 23-10-1996 01-06-1998 01-01-1997 02-07-1996 03-09-1996 07-07-1996 10-01-1996 22-02-1995 12-07-1995 26-07-1995 27-10-1995 30-04-1997 28-08-1995 28-05-1997 12-07-1995 27-04-1997 15-03-1995 02-01-1995 03-07-1995 30-04-1995 26-08-1997 06-05-1998 01-06-1995 20-12-1996 20-04-1997 01-08-1995 02-07-1995 03-09-1995 26-06-1998 30-11-1995 30-11-1995 20-03-1998 28-02-1997 05-11-1997 03-11-1998 26-08-1997 27-12-1996 25-03-1997 09-07-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR99/00347

EP A1	668352	23-08-1995	JP T2	8510921	19-11-1996
WO A2			9521919	17-09-1995	
WO A3			9521919	07-12-1995	
AU A1		16718795		29-08-1995	
AU B2		702669		04-03-1996	
DE A		9505781		05-03-1996	
CA AA		2160591		17-08-1995	
JP A1		695355		07-02-1996	
IT A0		954889		13-10-1995	
IT A		954889		10-11-1995	
IL A0		9503187		29-01-1996	
IL A2		75656		29-05-1997	
JP A2		8228781		10-09-1996	
JP A2		8277296		22-10-1996	
JP A2		8291196		05-11-1996	
NZ A		775570		29-01-1996	
IL A1		111800		18-03-1996	
IL A0		112431		28-05-1996	
JP A2		8109195		30-04-1996	
ZO A0		954058		12-10-1996	
ZO A		954058		11-12-1996	
IL A		1131438		18-09-1996	
IL A		1163933		05-11-1997	
IL A		1163974		05-11-1997	
ZA A		9501199		14-08-1996	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.